DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity.
Alexander MuikHomer C Adams 3rdFriederike GiesekeIsil AltintasKristina B SchoedelJordan M BlumBianca SängerSaskia M BurmEliana StanganelloDennis VerzijlVanessa M SpiresFulvia VascottoAras TokerJuliane QuinkhardtMark FereshtehMustafa DikenDavid P E SatijnSebastian KreiterTahamtan AhmadiEsther C W BreijÖzlem TüreciKate SasserUgur SahinMaria Jure-KunkelPublished in: Journal for immunotherapy of cancer (2022)
DuoBody-CD40×4-1BB is capable of enhancing antitumor immunity by modulating DC and T-cell functions and shows biological activity in patients with advanced solid tumors. These findings demonstrate that targeting of these two pathways with an Fc-inert bispecific antibody may be an efficacious approach to (re)activate tumor-specific immunity and support the clinical investigation of DuoBody-CD40×4-1BB for the treatment of cancer.